MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze CMPS →
    • FindStock Picks / Stock Screener
    • Value · CMPSIntrinsic Value Calculator
    • Invest · CMPSInvestment Case
    • Hold · CMPS5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
CMPS

CMPS

COMPASS Pathways plc

$10.75
-0.87
 (-7.49%)
Exchange:  NASDAQ
Market Cap:  1.489B
Shares Outstanding:  17.259M
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  BiotechnologyView industry performance
   
CEO:  Kabir Kumar Nath
Full Time Employees:  156
Address: 
33 Broadwick Street
London
CH
W1F 0DQ
GB
Website:  https://compasspathways.com
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
CMCMPS logoCMPSCOMPASS Pathways plc1.5B——-129.7%
ININVA logoINVAInnoviva, Inc.1.5B4.48.68.4%
OCOCUL logoOCULOcular Therapeutix, Inc.1.5B——-50.2%
QUQURE logoQUREuniQure N.V.1.5B——-22.5%
IMIMCR logoIMCRImmunocore Holdings plc1.5B——13.6%
KLKLRA logoKLRAKailera Therapeutics, Inc.1.5B——-18.3%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/05/13 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue000
Gross Profit000
EBITDA-115,238-148,816-285,602
Operating Income-136,919-178,205-179,037
Net Income-118,464-155,122-287,862

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets275,987213,666210,349
Total Liabilities50,24358,971263,197
Total Stockholders Equity225,744154,695-52,848
Total Debt33,05032,19320,925
Cash and Cash Equivalents220,198165,081149,608

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-97,753.436-119,186-157,240
Capital Expenditure-66.25500
Free Cash Flow-97,819.691-119,186-157,240
Net Income-118,923.174-155,122-287,862
Net Change in Cash77,257-55,168-15,483

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)282,850.665Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)1,918,296.531Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)788,129.591Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)31,659.083Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)482,819.921Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)171,047.572Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)22,005.428Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)378,422.490Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)132,122.334Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)0Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)0Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)0Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)1.410Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)4.050Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)0.240Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)6Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)4Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
0  ?P/S
 (TTM)
: 
0
?Net Income
 (TTM)
: 
-155.187M  ?P/E
 (TTM)
: 
-2.15
?Enterprise Value
 (TTM)
: 
1.24B  ?EV/FCF
 (TTM)
: 
-7.7
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
-398.21%  ?ROIC
 (TTM)
: 
-129.74%
?Net Debt
 (TTM)
: 
-133.277M  ?Debt/Equity
 (TTM)
: 
0.65
?P/B
 (TTM)
: 
13.29  ?Current Ratio
 (TTM)
: 
1.3

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
N/AResearch AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates CMPS intrinsic value between $0.20 – $0.44 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate CMPS Intrinsic Value

Common questions about CMPS valuation

Is COMPASS Pathways plc (CMPS) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for COMPASS Pathways plc (CMPS) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is CMPS a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether CMPS trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is CMPS’s P/E ratio?

You can see CMPS’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for CMPS?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is CMPS a good long-term investment?

Whether CMPS fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for COMPASS Pathways plc

  • COMPASS Pathways plc intrinsic value calculatorEstimate what the business is worth
  • COMPASS Pathways plc 5-year outlookWhat has to go right, and what could go wrong
CMPS

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-7.49
MarketSnap

Trading Metrics:

Open: 11.55   Previous Close: 11.62
Day Low: 10.72   Day High: 11.55
Year Low: 4.88   Year High: 15.87
Price Avg 50: 13.36   Price Avg 200: 10.16
Volume: 2.907M   Average Volume: 3.275M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Stock Has Consensus Target Price of $23.36 According to Brokerages
01-10-2026 04:29
Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Stock Has Consensus Target Price of $23.36 According to Brokerages
COMPASS Pathways plc (CMPS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
16-09-2026 14:31
COMPASS Pathways plc (CMPS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
COMPASS Pathways plc (CMPS) Discusses Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile in Depression Transcript
07-07-2026 17:32
COMPASS Pathways plc (CMPS) Discusses Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile in Depression Transcript

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze CMPS →
    • FindStock Picks / Stock Screener
    • Value · CMPSIntrinsic Value Calculator
    • Invest · CMPSInvestment Case
    • Hold · CMPS5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Settings
    • Public profile ↗
  • Log in

Media

Watch Listen Read